DexCom, Inc. - Common Stock (DXCM)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Aug 22, 2026Investment Snapshot
- Trading 255% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- Strong ROE of 34.8% with 18.7% net margin
- Revenue growing at 16% annually
DexCom, Inc. - Common Stock (DXCM) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $26.1 billion . Key value metrics: P/E ratio 28.6, P/B ratio 9.94, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
DexCom, Inc. - Common Stock — Fundamental Analysis Summary
DexCom, Inc. - Common Stock (DXCM) is currently trading 255% above its Graham Number of $19.44, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 28.6x.
On financial health, DXCM shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 34.8% (sector average: -20.1%), and elevated leverage with a debt-to-equity ratio of 1.31.
StockPik's composite Value Score for DXCM is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DXCM reports a high gross margin of 61.7% (sector average: 37.4%) and a strong operating margin of 21.1%.
DXCM shows revenue growing at 16% year-over-year, with earnings growing at 45%.